Abstract
Rifampin, a protein synthesis inhibitor, reduced mortality in a mouse model of meningitis compared to bacteriolytic cephalosporin standard therapy. To assess whether moxifloxacin (known to cause a less rapid bacteriolysis than cephalosporins) can similarly reduce mortality, mice infected with Streptococcus pneumoniae by deep intracerebral injection were treated subcutaneously with either 200 mg/kg of moxifloxacin or ceftriaxone every 8 hours for 5 days (n = 49 each). They were then observed for an additional 8 days. Overall mortalities were 35 and 29 in moxifloxacin- and ceftriaxone-treated mice, respectively (p = 0.29). Kaplan-Meier survival analysis also revealed no statistically significant differences (p = 0.32). Moxifloxacin failed to reduce mortality compared to cephalosporin standard therapy.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / pharmacokinetics
-
Anti-Bacterial Agents / therapeutic use*
-
Aza Compounds / administration & dosage
-
Aza Compounds / pharmacokinetics
-
Aza Compounds / therapeutic use*
-
Ceftriaxone / administration & dosage
-
Ceftriaxone / pharmacokinetics
-
Ceftriaxone / therapeutic use*
-
Disease Models, Animal
-
Drug Administration Schedule
-
Fluoroquinolones
-
Injections, Subcutaneous
-
Male
-
Meningitis, Pneumococcal / drug therapy*
-
Meningitis, Pneumococcal / mortality
-
Meningitis, Pneumococcal / pathology
-
Mice
-
Mice, Inbred C57BL
-
Moxifloxacin
-
Quinolines / administration & dosage
-
Quinolines / pharmacokinetics
-
Quinolines / therapeutic use*
-
Treatment Outcome
Substances
-
Anti-Bacterial Agents
-
Aza Compounds
-
Fluoroquinolones
-
Quinolines
-
Ceftriaxone
-
Moxifloxacin